CLINICAL TRIALS AND ORAL CANCER

Tìm thấy 10,000 tài liệu liên quan tới từ khóa "CLINICAL TRIALS AND ORAL CANCER":

UNIQUE PERCEPTION OF CLINICAL TRIALS BY KOREAN CANCER PATIENTS

UNIQUE PERCEPTION OF CLINICAL TRIALS BY KOREAN CANCER PATIENTS

In the past few years, the number of clinical trials has increased rapidly in East Asia, especially for gastric and hepatobiliary cancer that are prevalent in Asian populations. However, the actual degree of understanding or perceptions of clinical trials by cancer patients in East Asian countries h[r]

Đọc thêm

Access to clinical trials among oncology patients: Results of a cross sectional survey

Access to clinical trials among oncology patients: Results of a cross sectional survey

Clinical trials are necessary for the advancement of cancer treatment and care, however low rates of participation in such trials limit the generalisability of findings.

Đọc thêm

Are cancer patients better off if they participate in clinical trials? A mixed methods study

ARE CANCER PATIENTS BETTER OFF IF THEY PARTICIPATE IN CLINICAL TRIALS? A MIXED METHODS STUDY

Research and cancer care are closely intertwined; however, it is not clear whether physicians and nurses believe that clinical trials offer the best treatment for patients and, if so, whether this belief is justified.

17 Đọc thêm

PERCEPTIONS OF AND DECISION MAKING ABOUT CLINICAL TRIALS IN ADOLESCENT AND YOUNG ADULTS WITH CANCER: A QUALITATIVE ANALYSIS

PERCEPTIONS OF AND DECISION MAKING ABOUT CLINICAL TRIALS IN ADOLESCENT AND YOUNG ADULTS WITH CANCER: A QUALITATIVE ANALYSIS

Adolescent and young adults (AYA) enrolment rates into cancer clinical trials (CCT) are the lowest of any age group globally. As AYA have distinct biological, psychosocial and relational needs, we aimed to explore any unique factors influencing their CCT decision-making process, including AYA-specif[r]

Đọc thêm

PARTNERING AROUND CANCER CLINICAL TRIALS (PACCT): STUDY PROTOCOL FOR A RANDOMIZED TRIAL OF A PATIENT AND PHYSICIAN COMMUNICATION INTERVENTION TO INCREASE MINORITY ACCRUAL TO PROSTATE CANCER

PARTNERING AROUND CANCER CLINICAL TRIALS (PACCT): STUDY PROTOCOL FOR A RANDOMIZED TRIAL OF A PATIENT AND PHYSICIAN COMMUNICATION INTERVENTION TO INCREASE MINORITY ACCRUAL TO PROSTATE CANCER

Cancer clinical trials are essential for testing new treatments and represent state-of-the-art cancer treatment, but only a small percentage of patients ever enroll in a trial. Under-enrollment is an even greater problem among minorities, particularly African Americans, representing a racial/ethnic[r]

Đọc thêm

Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trials

CLINICAL OUTCOMES OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR IN PHASE I CLINICAL TRIALS

The prognosis of patients with gastrointestinal stromal tumor (GIST) after the failure of standard therapies is poor with supportive care alone. Guidelines recommend clinical trials, and patients with good performance status following standard therapies are often eligible for phase I clinical trials[r]

9 Đọc thêm

The efficacy and safety of crizotinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: A meta-analysis of clinical trials

THE EFFICACY AND SAFETY OF CRIZOTINIB IN THE TREATMENT OF ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER: A META-ANALYSIS OF CLINICAL TRIALS

Crizotinib was granted accelerated approval by the Food and Drug Administration in 2011 for the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). To evaluate the efficacy and safety of crizotinib, we performed a meta-analysis of published clinical trials usin[r]

6 Đọc thêm

USE AND MISUSE OF COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS IN CANCER CLINICAL TRIALS

USE AND MISUSE OF COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS IN CANCER CLINICAL TRIALS

Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) were released in 2003 and have been used widely to report toxicity in publications or presentations describing cancer clinical trials. Here we evaluate whether guidelines for reporting toxicity are followed in publications repo[r]

Đọc thêm

Effect of individualized communication skills training on physicians’ discussion of clinical trials in oncology: Results from a randomized controlled trial

Effect of individualized communication skills training on physicians’ discussion of clinical trials in oncology: Results from a randomized controlled trial

Discussing randomized clinical trials (RCTs) with cancer patients is one of the most challenging communication tasks a physician faces. Only two prior Communication Skills Trainings (CSTs) focused on RCTs in oncology have been reported. Their results demonstrated the need for further improvement.

Đọc thêm

Cancer Clinical Trials: Participation by Underrepresented Populations doc

CANCER CLINICAL TRIALS: PARTICIPATION BY UNDERREPRESENTED POPULATIONS DOC

THE DATA PRESENTED IN THE FIGURES AT RIGHT SHOW ACCRUAL RATES BY RACIAL AND ETHNIC STATUS: ENROLLMENT BY RACE AND ETHNICITY NATIONAL CANCER INSTITUTE, PUBLICLY FUNDED CANCER CLINICAL TRI[r]

4 Đọc thêm

DEFERASIROX, A NOVEL ORAL IRON CHELATOR, SHOWS ANTIPROLIFERATIVE ACTIVITY AGAINST PANCREATIC CANCER IN VITRO AND IN VIVO

DEFERASIROX, A NOVEL ORAL IRON CHELATOR, SHOWS ANTIPROLIFERATIVE ACTIVITY AGAINST PANCREATIC CANCER IN VITRO AND IN VIVO

Iron is essential for cell replication, metabolism and growth. Because neoplastic cells have high iron requirements due to their rapid proliferation, iron depletion may be a novel therapeutic strategy for cancer. Deferasirox (DFX), a novel oral iron chelator, has been successful in clinical trials i[r]

Đọc thêm

SRC-HOMOLOGY 2 DOMAIN-CONTAINING TYROSINE PHOSPHATASE 2 PROMOTES ORAL CANCER INVASION AND METASTASIS

SRC-HOMOLOGY 2 DOMAIN-CONTAINING TYROSINE PHOSPHATASE 2 PROMOTES ORAL CANCER INVASION AND METASTASIS

Tumor invasion and metastasis represent a major unsolved problem in cancer pathogenesis. Recent studies have indicated the involvement of Src-homology 2 domain-containing tyrosine phosphatase 2 (SHP2) in multiple malignancies; however, the role of SHP2 in oral cancer progression has yet to be elucid[r]

13 Đọc thêm

Nutritional assessment and prognosis of oral cancer patients: A large-scale prospective study

Nutritional assessment and prognosis of oral cancer patients: A large-scale prospective study

To evaluate and compare the prognostic performance of four nutritional indicators body mass index (BMI), serum albumin (ALB), prognostic nutritional index (PNI) and nutritional risk index (NRI) in oral cancer patients, and to predict the response to chemotherapy in patients with different nutritiona[r]

Đọc thêm

SUMMARY OF PHD THESIS: CLINICAL, SUBCLINICAL FEATURES AND RESISTANCE TO TYROSINE KINASE INHIBITOR OF LUNG CANCER PATIENTS WITH EGFR MUTATIONS

SUMMARY OF PHD THESIS: CLINICAL, SUBCLINICAL FEATURES AND RESISTANCE TO TYROSINE KINASE INHIBITOR OF LUNG CANCER PATIENTS WITH EGFR MUTATIONS

To describe the clinical and subclinical features of lung cancer patients with EGFR mutations before TKIs therapy and in the relapsed period. To identify the T790M mutation and MET amplification in patients with lung cancer and EGFR-TKIs resistance and the relationship with clinical and subclinical[r]

Đọc thêm

Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients

Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients

Over 20 % of ovarian cancer patients have preoperative thrombocytosis or hyperfibrinogenemia. We aimed to demonstrate the clinical and prognostic significance of thrombocytosis and hyperfibrinogenemia in high-grade serous ovarian cancer (HGSC).

Đọc thêm

SUBCELLULAR DIFFERENTIAL EXPRESSION OF EP-ICD IN ORAL DYSPLASIA AND CANCER IS ASSOCIATED WITH DISEASE PROGRESSION AND PROGNOSIS

SUBCELLULAR DIFFERENTIAL EXPRESSION OF EP-ICD IN ORAL DYSPLASIA AND CANCER IS ASSOCIATED WITH DISEASE PROGRESSION AND PROGNOSIS

Identification of patients with oral dysplasia at high risk of cancer development and oral squamous cell carcinoma (OSCC) at increased risk of disease recurrence will enable rigorous personalized treatment. Regulated intramembranous proteolysis of Epithelial cell adhesion molecule (EpCAM) resulting[r]

10 Đọc thêm

TUMOR APELIN, NOT SERUM APELIN, IS ASSOCIATED WITH THE CLINICAL FEATURES AND PROGNOSIS OF GASTRIC CANCER

TUMOR APELIN, NOT SERUM APELIN, IS ASSOCIATED WITH THE CLINICAL FEATURES AND PROGNOSIS OF GASTRIC CANCER

To study the association between Apelin expression and the clinical features and postoperative prognosis in patients with gastric cancer (Int J Cancer 136:2388-2401, 2015). Methods: Tumor samples and matched adjacent normal tissues were collected from 270 patients with GC receiving surgical resectio[r]

Đọc thêm

RANDOMIZED PHASE III TRIAL OF RADIOTHERAPY OR CHEMORADIOTHERAPY WITH TOPOTECAN AND CISPLATIN IN INTERMEDIATE-RISK CERVICAL CANCER PATIENTS AFTER RADICAL HYSTERECTOMY

RANDOMIZED PHASE III TRIAL OF RADIOTHERAPY OR CHEMORADIOTHERAPY WITH TOPOTECAN AND CISPLATIN IN INTERMEDIATE-RISK CERVICAL CANCER PATIENTS AFTER RADICAL HYSTERECTOMY

In cervical cancer patients with intermediate-risk factors, the optimal adjuvant therapy is still controversial. We undertook a randomized trial (ClinicalTrials.gov Identifier: NCT01418859) to compare the efficacy and toxicity of concurrent chemoradiotherapy with topotecan and cisplatin with radioth[r]

Đọc thêm

EXPRESSION AND CLINICAL SIGNIFICANCE OF MIR4516 AND MIR-21-5P IN SERUM OF PATIENTS WITH COLORECTAL CANCER

EXPRESSION AND CLINICAL SIGNIFICANCE OF MIR4516 AND MIR-21-5P IN SERUM OF PATIENTS WITH COLORECTAL CANCER

This study sought to detect the expression and clinical significance of miR-4516 and miR-21-5p in serum of patients with colorectal cancer.

Đọc thêm

CLINICAL AND PATHOLOGICAL FACTORS INFLUENCING SURVIVAL IN A LARGE COHORT OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS

CLINICAL AND PATHOLOGICAL FACTORS INFLUENCING SURVIVAL IN A LARGE COHORT OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS

To provide further information on the clinical and pathological prognostic factors in triple-negative breast cancer (TNBC), for which limited and inconsistent data are available.

Đọc thêm